Our previous study on the combined therapy of CASP3siRNA and CHBP (the cyclic form of HBSP with longer half‐life in the serum22) was observed at 48 h after kidney IR injury that showed the co‐treatment significantly reduced the expression of active 17 kDa caspase‐3 and HMGB1 as well as preserved kidney structure in comparison with single CASP3siRNA treatment or NCsiRNA and CHBP treatment.23 This evidence concerns the gene HMGB1 and medical procedure.